title: [Risk-sharing scheme in Israel--Kuvan as an allegory].
abstract: Healthcare systems worldwide are dealing with the uncertainty characterizing new and expensive health technoLogies, particularly aspects involving drug effectiveness and the extent and doses required for utilization. Reducing this uncertainty can be achieved mainly by using either coverage with evidence development methods or risk-sharing schemes (RSS). In 2011, the first phenylketonuria (PKU) risk-sharing scheme was set up in Israel, through the public funding health services updating process. This was done in order to ensure that people with PKU could access PKU sole treatment--sapropterin dihydrochloride, Kuvan. The apparent effectiveness of the treatment, on one hand, and the uncertainty regarding the number of patients and average treatment dosage, on the other hand, dictated the RRS. This scheme determined a ceiling number of tablets to be funded by the insurer, above this ceiling the manufacturer would finance Kuvan. Furthermore, it was agreed that after 3 years Kuvan would be brought to the public committee for updating reimbursement decisions. It is inevitable that risk sharing and conditional coverage agreements will become a common practice in the reimbursement process in the future. This will allow competent authorities and pharmaceutical companies to build clinical experience and other required data with medicines which might normally not be eLigible for reimbursement. Before it becomes the common practice in Israel, the RSS for Kuvan, process and outcomes, should be monitored and analyzed by the Ministry of Health, to ensure patients access to treatment, the effective collection of the research data and the effective interaction between Israel's four health funds and the manufacturer.
authors.forename: Ifat
authors.initials: I
authors.lastname: Abadi-Korek
authors.forename: Joshua
authors.initials: J
authors.lastname: Shemer
mesh_terms: D001708:Biopterins / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D003067:Coenzymes / Q000191:economics / Q000627:therapeutic use; D017047:Cost Sharing / Q000379:methods; D016527:Drug Costs / Q000639:trends; D006801:Humans; D007557:Israel; D054539:Medication Therapy Management / Q000458:organization & administration*; D010661:Phenylketonurias / Q000188:drug therapy / Q000191:economics; D012051:Reimbursement Mechanisms / Q000639:trends; D020414:Risk Sharing, Financial
chemical_list: D003067:Coenzymes; D001708:Biopterins; C003402:sapropterin